Neuronatin (NNAT)

Neuronatin (NNAT) is an imprinted proteolipid gene located on chromosome 20q11.23, preferentially expressed from the paternal allele[1][2]. It plays a critical role in brain development, regulation of ion channels, and maintenance of the nervous system structure[1][2][3][4]. NNAT is also implicated in cell cycle progression, proliferation, differentiation of keratinocytes, and insulin secretion in pancreatic β-cells. Aberrant gene expression and methylation status of NNAT are associated with numerous cancers (e.g., breast, kidney, lung, colorectal, thyroid, and hepatocellular carcinoma), neurodegenerative diseases such as Lafora disease, and metabolic conditions including diabetes and obesity[2][3]. NNAT can act as a tumor suppressor or oncogene depending on cellular context and has emerging relevance as a biomarker in oncology and metabolic disease research[2][3]. No evidence suggests a misspelling or an incorrect classification for NNAT; it is an accepted molecular target in both neurobiological and oncological research domains[1][2][3][4]. No interacting drugs or mechanisms of action established in current literature, reflecting its ongoing role as a biomarker and research target rather than a direct therapeutic molecular target[2].

Other names

NNATPeg5PEG5neuronatin

no established mechanism for therapeutic agents targeting NNAT available; note NNAT is a substrate for ubiquitin ligase malin, and involvement in calcium and insulin regulation is described[2]